Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Takeda Pharmaceutical Co's operating assets for the quarter that ended in Mar. 2026 was 円14,874,564 Mil. Takeda Pharmaceutical Co's operating liabilities for the quarter that ended in Mar. 2026 was 円3,199,019 Mil. Takeda Pharmaceutical Co's Total Assets for the quarter that ended in Dec. 2025 was 円15,408,774 Mil. Therefore, Takeda Pharmaceutical Co's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.76.
Takeda Pharmaceutical Co Scaled Net Operating Assets Related Terms
Takeda Pharmaceutical Co Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Takeda Pharmaceutical Co's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takeda Pharmaceutical Co Scaled Net Operating Assets Chart
TSE:4502 vs ZTS, UTHR: Scaled Net Operating Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takeda Pharmaceutical Co Scaled Net Operating Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Takeda Pharmaceutical Co's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.76 mean?
Takeda Pharmaceutical Co (TSE:4502) has a Scaled Net Operating Assets of 0.76 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Scaled Net Operating Assets too high?
Takeda Pharmaceutical Co's current Scaled Net Operating Assets is 0.76. Overall, Takeda Pharmaceutical Co has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Scaled Net Operating Assets compare to ZTS and UTHR?
Takeda Pharmaceutical Co's Scaled Net Operating Assets of 0.76 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Scaled Net Operating Assets is 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TSE:4502) is currently considered Modestly Overvalued. The stock's GF Value™ is 円4,534.12, compared to a current price of 円5,274.00 — trading 16.3% above its estimated fair value. The current Scaled Net Operating Assets is 0.76. Takeda Pharmaceutical Co's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TSE:4502), the current Scaled Net Operating Assets is 0.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takeda Pharmaceutical Co (TSE:4502) Overvalued in 2026?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円5,274.00 is trading 16.3% above its estimated GF Value™ of 円4,534.12.
GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for TSE:4502:
Scaled Net Operating Assets: 0.76
GF Value™: 円4,534.12 vs. price of 円5,274.00 (16.3% above fair value)
No single metric tells the full story. See the TSE:4502 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
65GF Score
Get the complete analysis for TSE:4502
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4502 has been successfully added to your 
